Objective: This study aims to compare the cost-effectiveness of insulin therapy, sulfonylureas, and combination of sulfonylureas-metformin in patients with type 2 diabetes mellitus in Sitanala Hospital, Tangerang. Methods:This study employed a cross-sectional to examine the effectiveness and cost of different treatments for Type 2 diabetes mellitus (T2DM) among outpatients at Dr. Sitanala Leprosy Hospital in Tangerang, using cost-effectiveness analysis. Participants had consumed the same drug over the past 4 months and were divided into three groups, as follows: An insulin group (n=29), sulfonylurea group (n=29), and sulfonylurea-metformin combination group (n=39). The effectiveness of treatment was evaluated by considering Hemoglobin A1c (HbA1c) values. The measured cost was direct medical cost. Results:The results showed that there were more female patients (65.96%) than male patients with T2DM, and their average age was 50-59 years. The highest effectiveness was shown in combination in the sulfonylurea-metformin group, with an HbA1c level of 7.48±1.89, although the difference was not statistically significant. The direct medical cost of sulfonylurea monotherapy was significantly lower than that of the other therapies. The average cost-to-effectiveness ratio in the insulin group was Rp. 40,866 that in the sulfonylurea group was Rp. 1,369 and that in the combination of sulfonylurea-metformin group was Rp. 2,621 per percentage of effectivity. The incremental cost-to-effectiveness ratio for the sulfonylurea-metformin to sulfonylurea monotherapy treatment was Rp. 16,194 per percentage effectivity. Conclusion:Based on the analysis performed, sulfonylurea-metformin combination therapy was more cost-effective than either sulfonylurea or insulin monotherapy.
Dengue fever is an infectious disease caused by virus transmitted through Aedes aegypty. The high incidence dengue fever can lead to increased healthcare costs. This study was conducted to analyze the effectiveness and direct cost of medical patients dengue fever without shock use fluid therapy by comparing crystalloid and crystalloid colloid combination. The subjects were 171 patients divided into two groups: 106 patients with crystalloid and 65 patients with crystalloid colloid combination. Assessed of effectiveness treatment and the mean medical costs. The results showed reviewed from hematocrit value no difference (p>0.05) in both study groups. The mean total cost of treatment for crystalloid Rp 4.005.223, the crystalloid colloid combination Rp 5.525.407. The highest cost of drug costs was 31.75% of the total cost crystalloid, 40.9% of the total cost crystalloid colloid combination. There was a significant difference between mean cost and two study groups (p0.05) with effectiveness treatment. Conclusion crystalloid have the same effectiveness as crystalloid colloid combination fluids at lower costs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.